TRILOGY/IMspire150: A phase 3, double-blinded, randomized study of atezolizumab (A) plus cobimetinib (C) combined with vemurafenib (V) vs. placebo plus C combined with v in previously untreated BRAFV600 mutation-positive patients with locally advanced or metastatic melanoma (NCT02908672/EudraCT 2016-002482-54) / Ascierto, P., Lewis, K., Mcarthur, G., Rooney, I., Mcnally, V.. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - 31:(2017), pp. 46-47.
TRILOGY/IMspire150: A phase 3, double-blinded, randomized study of atezolizumab (A) plus cobimetinib (C) combined with vemurafenib (V) vs. placebo plus C combined with v in previously untreated BRAFV600 mutation-positive patients with locally advanced or metastatic melanoma (NCT02908672/EudraCT 2016-002482-54)
Ascierto P;
2017
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
